These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 34148127)

  • 1. Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.
    Yang Z; Yin L; Zeng Y; Li Y; Chen H; Yin S; Zhang F; Yang W
    Virchows Arch; 2021 Nov; 479(5):947-959. PubMed ID: 34148127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
    Xie Z; Li X; Lun Y; He Y; Wu S; Wang S; Sun J; He Y; Xin S; Zhang J
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107090. PubMed ID: 33091816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
    Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
    Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Killing capacity analysis of tumor-infiltrating cytotoxic lymphocytes and impact on lymph node metastasis in differentiated papillary carcinoma of thyroid with the BRAF V600E mutation.
    Liu X; Liu H; Wang L; Han Y; Kong L; Zhang X
    Diagn Pathol; 2024 Feb; 19(1):29. PubMed ID: 38341587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment.
    Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Zhang J
    Front Endocrinol (Lausanne); 2020; 11():570604. PubMed ID: 33193087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a ferroptosis-related prognostic model for the prediction of progression-free survival and immune microenvironment in patients with papillary thyroid carcinoma.
    Huang Y; Xie Z; Li X; Chen W; He Y; Wu S; Li X; Hou B; Sun J; Wang S; He Y; Jiang H; Lun Y; Zhang J
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108156. PubMed ID: 34624650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bioinformatic analysis of CCND2 expression in papillary thyroid carcinoma and its impact on immune infiltration].
    Wang Q; Song B; Hao S; Xiao Z; Jin L; Zheng T; Chai F
    Nan Fang Yi Ke Da Xue Xue Bao; 2024 May; 44(5):981-988. PubMed ID: 38862457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AHNAK2 is a novel prognostic marker and correlates with immune infiltration in papillary thyroid cancer: Evidence from integrated analysis.
    Zheng L; Li S; Zheng X; Guo R; Qu W
    Int Immunopharmacol; 2021 Jan; 90():107185. PubMed ID: 33218938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.
    Zhu C; Dai Y; Zhang H; Ruan Y; Zhou Y; Dai Y; Fan L; Jia T; Lu H; Chen Q
    Diagn Pathol; 2021 Aug; 16(1):84. PubMed ID: 34465342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Papillary thyroid carcinoma behavior: clues in the tumor microenvironment.
    Bergdorf K; Ferguson DC; Mehrad M; Ely K; Stricker T; Weiss VL
    Endocr Relat Cancer; 2019 Jun; 26(6):601-614. PubMed ID: 30965283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
    Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
    BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
    Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
    BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a three-immune-related gene signature prognostic risk model in papillary thyroid carcinoma.
    Gan X; Guo M; Chen Z; Li Y; Shen F; Feng J; Cai W; Xu B
    J Endocrinol Invest; 2021 Oct; 44(10):2153-2163. PubMed ID: 33620716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer.
    Nunes LM; Ayres FM; Francescantonio IC; Saddi VA; Avelino MA; Alencar Rde C; Silva RC; Meneghini AJ; Wastowski IJ
    Hum Immunol; 2013 Apr; 74(4):447-51. PubMed ID: 23261411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of treatment response in lymphogenic metastasized papillary thyroid cancer: a histopathological study.
    van Kinschot CMJ; Oudijk L; van Noord C; Korevaar TIM; van Nederveen FH; Peeters RP; van Kemenade FJ; Visser WE
    Eur J Endocrinol; 2024 May; 190(5):374-381. PubMed ID: 38652802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma.
    He W; Sun Y; Ge J; Wang X; Lin B; Yu S; Li Y; Hong S; Xiao H
    Front Endocrinol (Lausanne); 2023; 14():1076640. PubMed ID: 36843593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of biomarkers associated with cervical lymph node metastasis in papillary thyroid carcinoma: Evidence from an integrated bioinformatic analysis.
    Zhang Z; Zhao S; Wang K; Shang M; Chen Z; Yang H; Chen Y; Chen B
    Clin Hemorheol Microcirc; 2021; 78(2):117-126. PubMed ID: 33554894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TPO as an indicator of lymph node metastasis and recurrence in papillary thyroid carcinoma.
    Li X; Cheng R
    Sci Rep; 2023 Jul; 13(1):10848. PubMed ID: 37407700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low expression of
    Yang L; Zhang X; Zhang J; Liu Y; Ji T; Mou J; Fang X; Wang S; Chen J
    Future Oncol; 2022 Jan; 18(3):333-348. PubMed ID: 34756116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.